


Appl. No. : 10/661,139  
Filed : September 12, 2003

### REMARKS

The Examiner has required restriction to one of four inventions:

- |           |                       |   |
|-----------|-----------------------|---|
| Group I   | Claims 1-12 and 34-41 | Drawn to a pharmaceutical composition comprising a compound of genera I, II, III, IV, V, VI, VII or VIII or subgenera I(a), II(a), III(a), IV(a), V(a), VI(a), VII(a), VIII(a) and methods of preparing such compounds, classified in class 514, subclass 415, for example. |
| Group II  | Claims 13-19          | Drawn to a method for treating or preventing an allergic reaction and/or inhibiting cytokines or leukocytes comprising the administration of a compound of genera I, II, III, IV, V, VI, VII, VIII, classified in class 514, subclass 415, for example.                     |
| Group III | Claims 20-22          | Drawn to a method for treating or preventing asthma comprising the administration of a compound of genera I, II, III, IV, V, VI, VII, VIII, classified in class 514, subclass 415, for example.   |
| Group IV  | Claims 23-33          | Drawn to a method for inhibiting cellular proliferation comprising the administration of a compound of genera I, II, III, IV, V, VI, VII, VIII, classified in class 514, subclass 415, for example.   |

Applicants hereby elect, without traverse, to prosecute the claims directed to Group I, including Claims 1-12 and 34-41. Applicants hereby elect Compound S-97, shown below:



as the single disclosed species.

Appl. No. : 10/661,139  
Filed : September 12, 2003

Claims 1 and 4-12 have been amended and Claims 13-33 have been withdrawn. Claims 1 and 4-12 have been amended to recite compounds *per se*. Support for this amendment can be found throughout the Specification and claims as filed, with references to the compounds *per se*. Accordingly, no new matter is being added herewith.


Claims 13-33 have been withdrawn as being directed to non-elected inventions. Applicants reserve the opportunity to rejoin the withdrawn claims upon allowance of the product claims in accordance with M.P.E.P. 821.04.

Should there be any questions concerning this application, the Examiner is respectfully invited to contact the undersigned at telephone number appearing below. Please charge any additional fees, including any fees for additional extension of time, or credit overpayment to Deposit Account No. 11-1410.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: January 9, 2006

By:   
Connie C. Tong  
Registration No. 52,292  
Agent of Record  
Customer No. 20,995  
(949) 760-0404

2216411  
121605